Axamon, 5 mg/ml 1 ml 10 pcs

Axamon® is a reversible cholinesterase inhibitor and directly stimulates impulse conduction at the neuromuscular synapse and in the central nervous system (CNS) due to blockade of membrane potassium channels. It enhances the effect on smooth muscles not only of acetylcholine but also of adrenaline, serotonin, histamine and oxytocin.

Axamon® has the following pharmacological effects:

– improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;

– improves conduction in the peripheral nervous system, impaired due to trauma, inflammation, exposure to local anesthetic, some antibiotics, potassium chloride, etc.

– increases the contractility of smooth-muscular organs under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, except for potassium chloride;

– improves memory, inhibits the progradient development of dementia.

It does not have teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects. It does not influence the endocrine system.

Indications

diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies;
diseases of the central nervous system: bulbar paralysis and paresis;
recovery period of organic lesions of the central nervous system, accompanied by motor disorders;
intestinal atony.

Pharmacological effect

Axamon® is a reversible cholinesterase inhibitor that directly stimulates impulse conduction at the neuromuscular synapse and in the central nervous system (CNS) due to blockade of membrane potassium channels. It enhances the effect on smooth muscles of not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin.

Aksamon® has the following pharmacological effects:

– improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;

– improves conductivity in the peripheral nervous system, impaired due to injury, inflammation, exposure to local anesthetics, some antibiotics, potassium chloride, etc.;

– enhances the contractility of smooth muscle organs under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride;

– improves memory, inhibits the progressive development of dementia.

Does not have teratogenic, embryotoxic, mutagenic, carcinogenic or immunotoxic effects. Does not affect the endocrine system.

Special instructions

During treatment, you should refrain from driving a car, other vehicles and machinery, as well as from engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Ipidacrine

Composition

1 ml of the drug contains:

Contraindications

Hypersensitivity to any of the components of the drug,
epilepsy,
extrapyramidal disorders with hyperkinesis,
angina pectoris
severe bradycardia,
bronchial asthma,
mechanical obstruction of the intestine or urinary tract,
vestibular disorders,
peptic ulcer of the stomach or duodenum in the acute stage,
children under 18 years of age (no systematic data on use).

With caution in case of: gastric and duodenal ulcers, thyrotoxicosis, diseases of the cardiovascular system, a history of obstructive diseases of the respiratory system or acute respiratory diseases.
If you have one of the listed diseases, be sure to consult your doctor before taking the drug.

Side Effects

The frequency of adverse reactions that may occur during use of the drug is given in the following classification: very common (>1/10 prescriptions), common (1/10-1/100 prescriptions), infrequent (1/100-1/1000 prescriptions), rare (1/1000-1/10000 prescriptions), very rare (Mental disorders: infrequent – drowsiness.

Interaction

Axamon® enhances the sedative effect in combination with drugs that depress the central nervous system.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, constriction of the pupils, nystagmus, increased peristalsis of the gastrointestinal tract, spontaneous bowel movements and urination, vomiting, jaundice, bradycardia, intracardiac conduction disorders, arrhythmias, decreased blood pressure, restlessness, anxiety, agitation, feelings of fear, ataxia, convulsions, coma, speech disorders, drowsiness and general weakness.

Storage conditions

In a place protected from light at a temperature not exceeding 25 °C.

Shelf life

2 years.

Manufacturer

Ellara LLC, Russia